# **Westminster Health Forum Keynote Seminar:**

## Next steps for specialised services and commissioning - funding, collaboration and leadership

Timing: Morning, Tuesday, 22<sup>nd</sup> November 2016

Venue: Glaziers Hall, 9 Montaque Close, London SE1 9DD

Agenda subject to change



	HEALTH FO
8.30 - 9.00	Registration and coffee
9.00 - 9.05	Chair's opening remarks Lord Sharkey, Vice Chair, Specialised Healthcare Commissioning Alliance
9.05 - 9.40	Implementing the Forward View for specialised services - priorities for NHS England  Dr Jonathan Fielden, Director of Specialised Commissioning and Deputy National Medical Director, NHS England Questions and comments from the floor
9.40 - 9.50	Assessing the funding challenge for specialised services  Robert White, Director, Health Value for Money Audit, National Audit Office
9.50 - 10.10	Key issues for collaboration in commissioning joined-up specialised services  Dr Etheldreda Kong, Chair, NHS Brent Clinical Commissioning Group  Vaughan Lewis, Clinical Director, NHS South Specialist Commissioning, NHS England
10.10 - 10.35	Questions and comments from the floor
10.35 - 10.40	Chair's closing remarks Lord Sharkey, Vice Chair, Specialised Healthcare Commissioning Alliance
10.40 - 11.10	Coffee

## 11.10 - 11.15 Chair's opening remarks

Baroness Masham of Ilton, Co-Chair, All-Party Parliamentary Health Group

#### 11.15 - 11.40 Developing the role of Clinical Reference Groups and providing expert support

**Dr Margaret Murphy**, Chair, Secure and Specialised Mental Health Programme of Care, NHS England Questions and comments from the floor

# 11.40 - 12.45 Priorities for delivery: population health, clinical leadership and provider models

With the budget for commissioning specialised services expanding by 7% in 2016/17, but also new costs associated with developing innovative treatments such as Proton Beam Therapy, how should NHS England approach the challenge of streamlining and improving the quality of care and at the same time reducing unwarranted variation in patient outcomes? How can commissioners improve the quality of care for a small number of patients with rare diseases, given an increasing demand for innovative treatments? With the strategic framework for specialised services advocating new models of collaboration between providers, what more needs to be done to ensure that patient need is met across a local population? In light of recent changes to the remit and number of Clinical Reference Groups (CRGs), what more should be done to improve clinical leadership for specialised services and spread best practice? What role should commissioning support play in meeting the aims of the strategic framework, particularly in encouraging place-based care and ensuring financial sustainability for specialised services?

Dr Niamh Lennox-Chhugani, Health and Social Care Lead, Optimity Advisors

Roger Spencer, Chief Executive, The Christie NHS Foundation Trust

Mike Ringe, NHS Strategy and Market Access Manager, ABPI

Sarah Radcliffe, Senior Policy and Campaigns Manager, National AIDS Trust

Dr Susan Walsh, Director, Primary Immunodeficiency UK and Head of Research and Patient Services,

The Chronic Granulomatous Disorder Society Questions and comments from the floor

## 12.45 - 12.55 Keynote closing remarks

Dr Jonathan Fielden, Director of Specialised Commissioning and Deputy National Medical Director, NHS England

# 12.55 - 13.00 Chair's and Westminster Health Forum closing remarks

**Baroness Masham of Ilton**, Co-Chair, All-Party Parliamentary Health Group **Sam Dolton**, Producer, Westminster Health Forum